These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37170090)

  • 1. Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials.
    Elmakaty I; Abdo R; Elsabagh A; Elsayed A; Malki MI
    Cancer Cell Int; 2023 May; 23(1):90. PubMed ID: 37170090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
    Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
    Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
    BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
    Qi Y; Yan X; Wang C; Cao H; Liu G
    Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
    [No Abstract]   [Full Text] [Related]  

  • 8. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
    Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
    Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
    Liang J; Li M; Sui Q; Hu Z; Bian Y; Huang Y; Zhan C; Jiang W; Wang Q; Tan L
    Transl Lung Cancer Res; 2020 Aug; 9(4):1302-1323. PubMed ID: 32953506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Cui W; Luo Q; Sun SL; Xu JL; Gu H
    Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Li Y; Xing L; Li F; Liu H; Gan L; Yang D; Wang M; Yin X; Li H; Ren G
    Front Oncol; 2021; 11():657634. PubMed ID: 34912699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis.
    Mittal N; Singh S; Mittal R; Kaushal J; Kaushal V
    J Cancer Res Ther; 2022; 18(6):1754-1765. PubMed ID: 36412440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis.
    Gao X; Zhu Y; Wang P; Yu L; Ruan S; Shen M; Zhang K
    Cancer Med; 2023 Dec; 12(24):21873-21884. PubMed ID: 38063264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer.
    Qi Y; Zhang W; Jiang R; Xu O; Kong X; Zhang L; Fang Y; Wang J; Wang J
    Front Pharmacol; 2022; 13():960323. PubMed ID: 36188589
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.